CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 275 enrolled
Drug / intervention
Bemnifosbuvir +1 moredrug
Likely dose
Bemnifosbuvir 550 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05904470
NCT05904470Phase 2Completed
CompareCT.gov

A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) Infection

Atea Pharmaceuticals, Inc.·interventional·Posted Jun 15, 2023·Updated Oct 21, 2025

In Brief

A Phase 2 clinical trial evaluating Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus and 4 related conditions. Completed, enrolled 275 participants across 51 sites in 12 countries.

Detailed Summary

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV
CountriesBrazil, Canada, India, Mauritius, Moldova, Pakistan, Philippines, Romania, South Africa, South Korea, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedJun 15, 2023
Enrollment StartMay 30, 2023
Primary CompletionDec 9, 2024
Study CompletionJan 28, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.0 years ago

Interventions

Bemnifosbuvirdrug

550 mg administered orally once a day (QD) for 8 weeks

Ruzasvirdrug

180 mg administered orally once a day (QD) for 8 weeks